Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This observational or N/A phase trial investigates Inflammation and Pathologic Processes and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 64 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)D-dimer, a fibrin degradation product generated as a result of plasmin mediated clot dissolution processes, is an indicator of recent clot formation and subsequent fibrinolysis. Analysis of D-dimer concentration is employed in the diagnosis of deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation. More recently, D-dimer levels have been correlated with atherosclerotic cardiovascular disease. In a recent case-control study of biomarkers for cardiovascular disease in human immunodeficiency virus (HIV)-infected adults, baseline D-dimer levels strongly correlated with all-cause mortality. Notably, the association between baseline D-dimer levels and death due to cardiovascular disease was less significant. At present, the pathophysiology underlying the association of elevated D-dimer concentrations with mortality in HIV is not understood. This study seeks to identify possible mechanisms underlying D-dimer elevations in HIV-infected adults by investigating a number of pathways that may be associated with the elevations using biomarkers of inflammation, hemostasis, thrombosis, platelet function, lipid metabolism, and additional indicators of endothelial function. Further elucidation of plausible pathways contributing to D-dimer elevation could, ultimately, lead to trials of risk-reducing interventions for patients with an elevated D-dimer level. This study, an exploratory, cross-sectional study of up to 350 subjects, seeks to prospectively collect data on D-dimer and related biomarkers...
D-dimer, a fibrin degradation product generated as a result of plasmin mediated clot dissolution processes, is an indicator of recent clot formation and subsequent fibrinolysis. Analysis of D-dimer concentration is employed in the diagnosis of deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation. More recently, D-dimer levels have been correlated with atherosclerotic cardiovascular disease. In a recent case-control study of biomarkers for cardiovascular disease in human immunodeficiency virus (HIV)-infected adults, baseline D-dimer levels strongly correlated with all-cause mortality. Notably, the association between baseline D-dimer levels and death due to cardiovascular disease was less significant.
At present, the pathophysiology underlying the association of elevated D-dimer concentrations with mortality in HIV is not understood. This study seeks to identify possible mechanisms underlying D-dimer elevations in HIV-infected adults by investigating a number of pathways that may be associated with the elevations using biomarkers of inflammation, hemostasis, thrombosis, platelet function, lipid metabolism, and additional indicators of endothelial function. Further elucidation of plausible pathways contributing to D-dimer elevation could, ultimately, lead to trials of risk-reducing interventions for patients with an elevated D-dimer level.
This study, an exploratory, cross-sectional study of up to 350 subjects, seeks to prospectively collect data on D-dimer and related biomarkers in HIV-infected adults. Initially, the study will recruit HIV-infected adults with HIV viremia who are not taking antiretroviral therapy (ART) and compare their clinical histories and biomarker findings with those from (1) a group of HIV-infected adults with controlled HIV viremia who are receiving ART, and with those from (2) a control group of HIV-negative healthy subjects. Additionally, to study the impact of persistent immune activation and inflammation on immune responses to ART, a cohort of HIV-infected adults with poor CD4+ cell recovery despite effective ART, and to better understand the mechanisms that contribute to impaired immunologic recovery, a cohort of HIV-infected adults with poor CD4+ cell recovery despite effective ART will be enrolled (immunologic non-responder cohort) and for comparison, a control group with similar nadir CD4 counts but with good CD4+ cell recovery on ART.
The study requires 2 visits for screening, history and physical examination, and phlebotomy. A wide array of research assays investigating different aspects of inflammation, coagulation, and endothelial function will be completed. Samples will be stored for future investigation.
Status Flow
Change History
64 versions recorded-
Apr 16, 2026 — Present [daily]
Completed
-
Feb 2026 — Apr 2026 [monthly]
Completed
-
Nov 2025 — Feb 2026 [monthly]
Completed
-
Oct 2025 — Nov 2025 [monthly]
Completed
-
Aug 2025 — Oct 2025 [monthly]
Completed
▶ Show 59 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Completed
-
May 2025 — Jul 2025 [monthly]
Completed
-
Apr 2025 — May 2025 [monthly]
Completed
-
Dec 2024 — Apr 2025 [monthly]
Completed
-
Nov 2024 — Dec 2024 [monthly]
Completed
-
Oct 2024 — Nov 2024 [monthly]
Completed
-
Sep 2024 — Oct 2024 [monthly]
Completed
-
Aug 2024 — Sep 2024 [monthly]
Completed
-
Jul 2024 — Aug 2024 [monthly]
Completed
-
Jun 2024 — Jul 2024 [monthly]
Completed
Status: Enrolling By Invitation → Completed
-
May 2024 — Jun 2024 [monthly]
Enrolling By Invitation
-
Feb 2024 — May 2024 [monthly]
Enrolling By Invitation
-
Jan 2024 — Feb 2024 [monthly]
Enrolling By Invitation
-
Dec 2023 — Jan 2024 [monthly]
Enrolling By Invitation
-
Oct 2023 — Dec 2023 [monthly]
Enrolling By Invitation
-
Sep 2023 — Oct 2023 [monthly]
Enrolling By Invitation
-
Jul 2023 — Sep 2023 [monthly]
Enrolling By Invitation
-
May 2023 — Jul 2023 [monthly]
Enrolling By Invitation
-
Apr 2023 — May 2023 [monthly]
Enrolling By Invitation
-
Mar 2023 — Apr 2023 [monthly]
Enrolling By Invitation
-
Feb 2023 — Mar 2023 [monthly]
Enrolling By Invitation
-
Jan 2023 — Feb 2023 [monthly]
Enrolling By Invitation
-
Dec 2022 — Jan 2023 [monthly]
Enrolling By Invitation
-
Nov 2022 — Dec 2022 [monthly]
Enrolling By Invitation
-
Sep 2022 — Nov 2022 [monthly]
Enrolling By Invitation
Status: Recruiting → Enrolling By Invitation
-
Jul 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting
-
Apr 2022 — May 2022 [monthly]
Recruiting
-
Jan 2022 — Apr 2022 [monthly]
Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting
-
May 2021 — Sep 2021 [monthly]
Recruiting
-
Mar 2021 — May 2021 [monthly]
Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Recruiting
-
May 2020 — Jun 2020 [monthly]
Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Recruiting
-
Dec 2019 — Feb 2020 [monthly]
Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Recruiting
-
May 2019 — Oct 2019 [monthly]
Recruiting
-
Mar 2019 — May 2019 [monthly]
Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Recruiting
-
Sep 2018 — Jan 2019 [monthly]
Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study will collect information about markers of inflammation, blood clotting and blood vessel function in HIV-infected adults and healthy volunteers. Biomarkers are biological indicators that have been associated with disease. Certain markers of inflammation, blood clotting, and blood vessel function have been associated with risk of cardiovascular disease, stroke and death. One marker, called D-dimer, is a breakdown product of blood clots that has been associated with serious medical conditions, including deep vein thrombosis (formation of a blood clot in a vein deep in the body) and pulmonary embolism (blockage in the pulmonary artery that occurs when a blood clot from a vein breaks away, travels to the pulmonary artery and lodges there). High D-dimer levels have also been associated with cardiovascular disease and stroke risk. In a recent study of HIV-infected patients, higher D-dimer levels were strongly correlated with risk of death from any cause. The significance of changes in D-dimer and other biomarkers in HIV-infected adults is not well understood. This study will further explore D-dimer and other biomarkers to try to better understand the relationships between them and HIV infection. Healthy volunteers and HIV-infected adults 18 years of age or older may be eligible for this study. Two visits are involved, as follows: Visit 1 (screening visit to determine eligibility) * Medical history and physical examination. * Blood tests for HIV infection, blood counts, liver and kidney function. * Pregnancy test for women who can become pregnant. Visit 2 * Blood tests for hepatitis B and C * Blood tests for markers of inflammation and blood clotting. * Blood test for genetic changes that influence blood clotting. In some cases, visits 1 and 2 may be combined. Optional additional visits (up to 8 visits over 3 years) * Additional blood draws for investigation of specific clinical or laboratory findings may be requested.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .